Casirivimab and imdevimab, manufactured by US-based Regeneron, are included in the World Health Organization’s recommendations for treating mild cases of covid-19 in patients at increased risk of hospitalization, and for treating severe cases of the disease if untreated. People who do not have antibodies.

“Given the high cost and rarity of this combination therapy, WHO calls for Regeneron to reduce prices, equitably distribute it, particularly in low- and middle-income countries, and transfer technology to enable bio-identical versions to be manufactured for all patients who need them,” the organization said in a statement. access to it.”

The World Health Organization has already launched an appeal among pharmaceutical companies for them to apply versions of the drugs for prequalification, which will allow to increase the level of production.

He also stressed that treatment with the two drugs should not be given to patients who have antibodies to the Covid-19 virus in order to “not exacerbate inequality and limited treatment availability.”

The World Health Organization is also urging doctors to apply “rigorous testing” to patients to see what they would benefit most from this treatment, those who have not yet developed natural antibodies against Covid-19.